A Phase II Trial of 13-Cis Retinoic Acid, Alpha Interferon, Taxotere, and Estramustine (R.I.T.E.) for the Treatment of Hormone Refractory Prostate Cancer
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Response (biochemical and measurable disease)
研究概览
简要总结
RATIONALE: Isotretinoin may help prostate cancer cells become more like normal cells, and to grow and spread more slowly. Interferon alfa-2b may interfere with the growth of tumor cells. Drugs used in chemotherapy, such as docetaxel and estramustine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving isotretinoin and interferon alfa-2b together with docetaxel and estramustine may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving isotretinoin and interferon alfa-2b together with docetaxel and estramustine works in treating patients with metastatic prostate cancer that did not respond to hormone therapy.
详细描述
OBJECTIVES:
Primary
- Determine the response rate, in terms of change in measurable disease or prostate-specific antigen levels, in patients with hormone-refractory metastatic prostate cancer treated with isotretinoin, recombinant interferon alfa-2b, docetaxel, and estramustine phosphate sodium.
Secondary
- Determine the effect of this regimen on bcl-2 family proteins in peripheral blood mononuclear cell samples obtained from these patients.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Histologically confirmed hormone-refractory metastatic prostate cancer
- •Patients who have been recently withdrawn from treatment with bicalutamide or flutamide must demonstrate progression of disease
- •Measurable disease OR prostate-specific antigen level ≥ 10 ng/mL
- •PATIENT CHARACTERISTICS:
- •ECOG performance status 0-2
- •Estimated life expectancy ≥ 6 months
- •Absolute neutrophil count ≥ 1,500/mm³
- •Hemoglobin ≥ 8 g/dL
- •Platelet count ≥ 100,000/mm³
- •Creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 50 mL/min
- •Bilirubin normal
- •AST, ALT, and alkaline phosphatase (AP) must meet 1 of the following criteria:
- •AP normal and AST and ALT ≤ 2.5 times upper limit of normal (ULN)
- •AP elevated and AST and ALT normal
- •No history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80
- •No peripheral neuropathy > grade 1
- •No concurrent active infections
- •No concurrent major depression or suicidal ideation
- •No concurrent medical condition that would preclude study participation
- •No known HIV positivity
- •Fertile patients must use effective contraception during and for 10 weeks after completion of study therapy
- •PRIOR CONCURRENT THERAPY:
- •Recovered from prior surgery or radiotherapy
- •No prior chemotherapy, retinoids, or interferon therapy
- •More than 4 weeks since prior flutamide
- •More than 6 weeks since prior bicalutamide
排除标准
- 未提供
结局指标
主要结局
Response (biochemical and measurable disease)
Bcl-2 modulation in peripheral blood mononuclear cells
次要结局
未报告次要终点